EpistemisSacral edema in recumbency
Specialty: Cardiovascular.
Why it occurs
- Severe congestive heart failure (with patient in prolonged supine position)
- Refractory right ventricular failure
- Constrictive pericarditis with severe central venous hypertension
- Nephrotic syndrome or glomerulonephritis in an immobile patient
- Severe hypoalbuminemia associated with protein-losing enteropathy or cardiac cachexia
Initial workup
Determination of serum electrolytes (sodium, potassium, chlorine), creatinine, urea nitrogen, total proteins, albumin, and natriuretic peptides (BNP/NT-proBNP); Transthoracic Doppler echocardiogram to evaluate left and right ventricular function, and estimate right atrial pressure by analyzing the inferior vena cava; Ultrasound of soft tissues of the sacral region to differentiate edema from the development of incipient pressure ulcers or infected fluid collections.
red flags
Diffuse edematous swelling with pitting located over the sacral and lumbar region in a bedridden patient, accompanied by dyspnea at rest, severe orthopnea with the need to keep the head of the bed at 90 degrees, diffuse basal pulmonary wheezing and crackles, muffled heart sounds, severe oliguria (<400 mL in 24 hours), or venous distension prominent jugular. It indicates massive extracellular volume overload that, due to the effect of gravity, is located in the sacral region instead of the ankles, requiring intensive intravenous diuretic therapy to avoid pulmonary edema.
Standard management
- Furosemide — loop diuretic indicated for the rapid elimination of excess intravascular and interstitial volume; 40 to 120 mg intravenously per day, administered as a bolus or continuous infusion, adjusting according to diuretic rhythm under strict ionic monitoring
- Spironolactone — aldosterone antagonist useful to counteract sodium reabsorption in the collecting duct and prevent hypokalemia induced by loop diuretics; 25 to 50 mg once daily orally
- Hydrochlorothiazide — thiazide diuretic that can be associated with furosemide in cases of refractory diuretic resistance to achieve sequential blockage of the nephron; 25 mg once daily orally, monitoring for the appearance of severe hyponatremia or hypokalemia
- Sacubitril/Valsartan (indicated in the background treatment of stable chronic heart failure; 49/51 mg twice daily orally).
Educational guidance for study. It is NOT a prescription recommendation. The actual choice depends on the cause, the patient, and current guidelines.
- Area
- Cardiovascular
- Listed causes
- 5
- Treatment options
- 4